Yanez B, Gray RJ, Sparano JA, et al. - Researchers conducted the study for identifying the correlation between early discontinuation of endocrine therapy (ET) in the Trial Assigning Individualized Options for Treatment (TAILORx) and modifiable risk factors, polypharmacy, and types of additional medications like antidepressants and opioids. In total, 954 women (mean [SD] age, 56.6 [8.9] years) were involved in this analysis. All participants were diagnosed with hormone receptor-positive, ERBB2-negative, axillary node-negative breast cancer and began ET within a year of enrolling in the study. Baseline patient-reported health-related quality of life components like poor social well-being, poor physical well-being, and comorbid depression were significant risk factors for early discontinuation of endocrine therapies in this post hoc analysis of a randomized clinical trial. Such findings support the use of systematic screening for patient-reported outcomes and depressive symptoms to identify women who are at risk of discontinuing ET.